Countering pharmaceutical and medical counterfeiting and counterfeiting: the experience of the European Union
The article examines the directions of the European Union's policy regarding the development and implementation of legal and organizational measures to combat pharmaceutical and medical counterfeiting and falsiﬁcation from the point of view of ensuring the interests of copyright holders and public health in the context of digital transformations. It is shown that the legislation of the European Union, as well as the initiatives of the European Commission and a number of special bodies are aimed at increasing the eﬃciency of the protection of intellectual property rights as measures to combat counterfeiting in the healthcare sector, as well as countering the inﬂux of counterfeit pharmaceuticals and medical devices. Particular attention is paid to anti-counterfeiting and counterfeiting measures in the context of the COVID-19 pandemic.